Combined treatment with Ad‐hTRAIL and DTIC or SAHA is associated with increased mitochondrial‐mediated apoptosis in human melanoma cell lines
T Lillehammer, BO Engesaeter… - The Journal of Gene …, 2007 - Wiley Online Library
Background Currently, dacarbazine (DTIC) is the only approved systemic treatment for
metastatic malignant melanoma. However, the modest treatment effect encourages studies
on novel therapeutic molecules, delivery systems and combination therapies. Full‐length
TRAIL, delivered from an adenoviral vector (Ad‐hTRAIL), was studied in combination with
DTIC or the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in human
melanoma cell lines. Methods The cytotoxic potential of the combination treatments was …
metastatic malignant melanoma. However, the modest treatment effect encourages studies
on novel therapeutic molecules, delivery systems and combination therapies. Full‐length
TRAIL, delivered from an adenoviral vector (Ad‐hTRAIL), was studied in combination with
DTIC or the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in human
melanoma cell lines. Methods The cytotoxic potential of the combination treatments was …
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial mediated apoptosis in human melanoma cell lines
T Lillehammer, G Maelandsmo, O Fodstad… - Melanoma …, 2006 - journals.lww.com
Dacarbazine (DTIC), used as a single agent, is currently the mainstay treatment of metastatic
malignant melanoma; however, the response rates ranging from 13 to 20% are
disappointing, and thus the therapy is given more of a palliative intent. In attempts to
increase the response rate, studies of novel therapeutic molecules, delivery systems and
combination therapies are therefore highly desirable. TNF-related apoptosis-inducing ligand
(TRAIL) and histone deacetylase inhibitors (HDACI) have attracted attention owing to their …
malignant melanoma; however, the response rates ranging from 13 to 20% are
disappointing, and thus the therapy is given more of a palliative intent. In attempts to
increase the response rate, studies of novel therapeutic molecules, delivery systems and
combination therapies are therefore highly desirable. TNF-related apoptosis-inducing ligand
(TRAIL) and histone deacetylase inhibitors (HDACI) have attracted attention owing to their …
以上显示的是最相近的搜索结果。 查看全部搜索结果